Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor-Reference-Cited by-同舟云学术

Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor

Published:2017-10 Issue:4 Volume:92 Page:900-908
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Kiriakidis Serafim,Hoer Simon S.,Burrows Natalie,Biddlecome Gloria,Khan Moddasar N.,Thinnes Cyrille C.,Schofield Christopher J.,Rogers Norma,Botto Marina,Paleolog Ewa,Maxwell Patrick H.

Publisher

Elsevier BV

Subject

Nephrology

Reference41 articles.

1. Partial characterization of protocollagen from embryonic cartilage;Kivirikko;Biochem J,1967

2. Collagens, modifying enzymes and their mutations in humans, flies and worms;Myllyharju;Trends Genet,2004

3. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation;Epstein;Cell,2001

4. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor;Hirsilä;J Biol Chem,2003

5. Prolyl hydroxylase domain inhibitors: a route to HIF activation and neuroprotection;Harten;Antioxid Redox Signal,2010

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Roxadustat alleviates metabolic traits in letrozole-induced PCOS mice;Biochemical Pharmacology;2024-11

2. HIF Stabilizer Desidustat Protects against Complement-Mediated Diseases;Drug Research;2024-07-11

3. A preliminary study of roxadustat in the treatment of aplastic anemia patients with inadequate erythroid responses;Annals of Hematology;2024-05-22

4. Collagen prolyl 4-hydroxylase isoenzymes I and II have sequence specificity towards different X-Pro-Gly triplets;Matrix Biology;2024-01

5. Targeting hypoxia-inducible factors: therapeutic opportunities and challenges;Nature Reviews Drug Discovery;2023-12-20